Omnicell (OMCL) stock was in focus after the company reported second quarter 2026 earnings on July 30, showing higher revenue and net income, and issued updated full year revenue guidance.
See our latest analysis for Omnicell.
Omnicell’s share price has climbed over the past week but is still down 18.5% year to date, while the 1 year total shareholder return of 19.4% contrasts with weaker 3 and 5 year total returns. This hints that recent momentum is recovering off a low base after the stronger second quarter results and updated 2026 guidance.
If Omnicell’s move has you rethinking healthcare technology exposure, it could be a good moment to see what else is gaining attention in 43 healthcare AI stocks
Omnicell’s earnings jump and guidance update have helped the stock rebound, yet the multiyear share price record still looks weak. Is the recent move simply a catch-up, or does the current valuation leave further upside on the table?
Most Popular Narrative: 39.9% Undervalued
At a last close of $36.81 versus a narrative fair value of $61.29, Omnicell is framed as materially undervalued, with that gap resting on some specific growth and margin expectations.
The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.
Want to see the math behind that valuation gap? The core of this narrative is how earnings, revenue mix, and margins are expected to reset over time.
Result: Fair Value of $61.29 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Omnicell’s story can change quickly if tariff related costs stay elevated or if hospital capital budgets tighten and slow large automation projects.
Find out about the key risks to this Omnicell narrative.
Another View on Omnicell’s Valuation
The earlier narrative leans heavily on fair value estimates tied to future earnings and cash flows. Looking at Omnicell through its current P/E tells a different story. The stock trades at about 43x earnings, which is below peer averages of 66.7x but above the US Medical Equipment industry at 26.1x. The fair ratio of 27.9x suggests the market could shift closer to that level over time, which would leave less room for error if growth or margins fall short. Which signal do you trust more: the discount to fair value, or the richer multiple against the wider industry?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mix of optimism and caution around Omnicell might leave you with mixed feelings, so it helps to review the figures yourself and move quickly. To see what the current optimism focuses on, take a closer look at the 4 key rewards.
Looking for more Omnicell sized investment ideas?
Do not stop at Omnicell. A few minutes with targeted stock lists can reveal opportunities you might not otherwise spot, especially when markets move quickly.
- Zero in on quality by scanning companies that appear in the solid balance sheet and fundamentals stocks screener (49 results) to see which businesses back their stories with financial strength.
- Hunt for potential bargains by checking the 51 high quality undervalued stocks and compare how their valuations stack up against your existing watchlist.
- Strengthen your income stream by reviewing the 8 dividend fortresses and see which high yield stocks match your risk tolerance.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com